Document is current
Any future updates will be listed below
-
Authors
Strickler, John H. https://orcid.org/0000-0001-7579-1175
Rushing, Christel N.
Niedzwiecki, Donna
McLeod, Abigail
Altomare, Ivy
Uronis, Hope E.
Hsu, S. David
Zafar, S. Yousuf
Morse, Michael A.
Chang, David Z.
Wells, James L.
Blackwell, Kimberly L.
Marcom, P. Kelly
Arrowood, Christy
Bolch, Emily
Haley, Sherri
Rangwala, Fatima A.
Hatch, Ace J.
Nixon, Andrew B.
Hurwitz, Herbert I.
-
Funding
Funding for this research was provided by:
Sanofi-Aventis Korea Company
- License Information
-
More Information
Article History
Received: 28 February 2019
Accepted: 2 October 2019
First Online: 1 November 2019
Ethics approval and consent to participate
: This study was approved by the Duke Institutional Review Board and following the guidelines of the Helsinki Declaration. All patients provided informed written consent prior to any study-related procedure and were treated at Duke Cancer Institute.
: Not applicable.
: Dr. Blackwell discloses employment at Eli Lilly Corp. Dr. Hurwitz discloses employment, stock holdings, and consulting work with Genentech/Roche, as well receiving trial support from Regeneraon. Dr. Nixon discloses receiving consulting fees from Eli Lilly, Kanghong Pharma, GlaxoSmithKline, and Promega, as well as receiving research funding from Acceleron Pharma, Amgen, AstraZeneca/MedImmune, Eureka Therapeutics, Genentech, HTG Molecular Diagnostics, Leadiant Biosciences, MedPacto Inc., Novartis, Seattle Genetics, and Tracon Pharma. Dr. Strickler discloses receiving research funding from Seattle Genetics, Exelixis, Amgen, AbbVie, Genentech/Roche, and Sanofi Genzyme. Additionally, Dr. Strickler performs consulting and honoraria work for Amgen, Bayer, Chengdu, Kanghong Biotechnology, Genentech/ Roche, and Seattle Genetics. Dr. Zafar discloses membership on the advisory boards for AIM Specialty Health, Vivor, LLC, and SamFund. Additionally, Dr. Zafar is on the Board of Directors for the Family Reach Foundation, receives research funding from the NIH, and AstraZeneca, is a board member for Copernicus- WCG IRB, and is a consultant for RTI, McKesson, Discern, LLC, and Quintiles Corporation.
